<DOC>
	<DOCNO>NCT02769533</DOCNO>
	<brief_summary>This study focus patient present suspected malignancy pituitary gland consider good surgical candidates.The primary end-point study determine sensitivity OTL38 uptake expression identify nodule excite image probe.There single dose 0.025 mg/kg intravenous injection approximately 60 minute , two three hour , prior surgery .</brief_summary>
	<brief_title>A Phase 1 , Single Dose , Open-Label Study Investigate Safety Efficacy OTL38 Injection ( OTL38 ) Intra-operative Imaging Folate Receptor-alpha Positive Pituitary Adenoma</brief_title>
	<detailed_description />
	<mesh_term>Adenoma</mesh_term>
	<mesh_term>Pituitary Diseases</mesh_term>
	<mesh_term>Pituitary Neoplasms</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<criteria>Adult patient 18 year age Patients present pituitary nodule presume resectable preoperative assessment Good operative candidate Subject capable give informed consent participate process consent . Pregnant woman determine urinary serum beta hCG within 72 hour surgery Patients history anaphylactic reaction OTL38 Patients know allergy Benadryl Previous exposure OTL38</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>